TrialBreast cancer research and treatment2023

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.

Masahiro Takada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.